Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
December 11, 2017 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief...
Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results
November 09, 2017 08:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the third quarter of 2017. “We are...
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
October 24, 2017 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Trial to Enroll Approximately 190 Patients with Pruritus Associated with Psoriasis-- Top-Line Results Expected in First Half of 2019 WESTLAKE VILLAGE, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) --...
Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results
September 07, 2017 08:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the second quarter of 2017. “We are...
Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 01, 2017 16:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the closing of the Company’s initial public offering of 4,983,333 shares of...
Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
July 26, 2017 19:30 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the pricing of the Company’s initial public offering of 4,333,333 shares of...
Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors
June 14, 2017 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on bringing innovations in...